Drug intelligence / Profile preview

CTX010

Development stage: Preclinical
Lead developer: Vertex
Modality: Cell Therapies, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies
Administration: Intravenous

Overview

CTX010 is a preclinical-stage therapeutic candidate originally developed by Clover Therapeutics (now Character Biosciences) for the treatment of dry and wet age-related macular degeneration (AMD). Discovered through the company's precision medicine platform, which integrates genomics, longitudinal clinical data, and machine learning, CTX010 is designed to target specific molecular drivers of AMD progression. The exact target and modality of CTX010 have not been publicly disclosed.

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on CTX010.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTX010.

Explore the full profile